<DOC>
	<DOCNO>NCT02775006</DOCNO>
	<brief_summary>The objective study investigate effect docetaxel monotherapy combination docetaxel intercalate erlotinib patient relapse EGFR wild type , ALK negative non squamous cell carcinoma .</brief_summary>
	<brief_title>Docetaxel Versus Intercalated Erlotinib-docetaxel Patients With Relapsed EGFR Wild Type , ALK Negative Non Squamous Cell Carcinoma</brief_title>
	<detailed_description>The aim study investigate effect docetaxel monotherapy combination docetaxel intercalate erlotinib patient relapse EGFR wild type , ALK negative non squamous cell carcinoma . As pemetrexed standard first line treatment , combination erlotinib docetaxel non-squamous NSCLC investigate second line treatment . Also question answer whether combination outperforms monotherapy treatment . After stratification ECOG-performance status ( 0-1 ) , response prior treatment ( CR , PR , SD versus PD ) , treatment free interval platinum base therapy ( &lt; 6 month versus &gt; 6 month ) maintenance , patient centrally randomize receive either docetaxel ( arm A ) docetaxel plus erlotinib ( arm B ) .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Histologically cytologically confirm EGFR wild type , ALK negative , nonsquamous cell carcinoma , locally advanced metastatic disease stage IIIB IV . Evidence disease progression one cytotoxic treatment platinum contain regimen . Immunotherapy pretreatment allow 2 . Complete recovery prior chemotherapy side effect &lt; Grade 2 . 3 . At least one unidimensionally measurable lesion meeting RECIST criterion . 4 . ECOG PS 01 . 5 . Age ≥ 18 year . 6 . Adequate organ function , include : Adequate bone marrow reserve : ANC &gt; 1.5 x 109/L , platelet ≥ 100 x 109/L . Hepatic : bilirubin ≤1.5 x ULN ( upper limit normal ) , AP , ALT , AST ≤ 1.5 x ULN . AP , ALT , AST ≤5 x ULN acceptable liver tumor involvement . Renal : calculated creatinine clearance ≥ 40 ml/min base CockcroftGault formula . 7 . Male female patient reproductive potential must use approved contraceptive method , appropriate . Female patient childbearing potential must negative serum pregnancy test within 7 day prior study enrollment . 8 . Signed informed consent . 9 . Patient compliance geographical proximity allow adequate follow . 10 . Patients undergone cranial irradiation brain metastases 4 week inclusion protocol , provide clinically fit undergo second line treatment 1 . Pregnant lactating woman . 2 . Patients medical risk nonmalignant disease well active uncontrolled infection . 3 . Documented brain metastasis unless patient complete local therapy central nervous system metastases least 4 week enrollment corticosteroid least two week enrollment . Prophylactic irradiation least 4 week prior enrollment accept . 4 . Maintenance treatment erlotinib TKI ( Tyrosine Kinase Inhibitor ) , docetaxel . Maintenance treatment pemetrexed allow . Previous treatment EGFRTKI docetaxel within 6 month prior enrollment . 5 . Inability unwillingness take dexamethasone . 6 . Concomitant treatment experimental drug investigation . 7 . Patients experience disease progression within 2 month start platinum base chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>